About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon-Media
  > MEDIA
  Overview
  Press Releases
  Media Stories
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts
  
  
     
 

Biocon´s Insulins facility in Malaysia Receives EU GMP Compliance Certificate

Bengaluru, Karnataka, India and Malaysia
September 07, 2017:

“Biocon´s subsidiary in Malaysia, Biocon Sdn. Bhd., has been issued a Certificate of ´GMP Compliance´ for its Insulins manufacturing facility by the HPRA (Ireland) as the representative European inspection authority. The certificate of GMP compliance reflects that the agency considered the site to be in compliance with the principles and guidelines of Good Manufacturing Practices for Active Substances, Sterile Drug Products and Quality Control Testing operations. Biocon´s Malaysia facility was inspected by the EMA in April 2017.

Biocon Sdn. Bhd. (Biocon Malaysia) is one of Asia´s largest state-of-the-art integrated insulins manufacturing facilities, set up with an investment of about USD 275 million, at the BioXcell Biotech Park in Johor, Malaysia. This is the first overseas biopharma manufacturing & research facility of Biocon and it employs over 600 professionals. The facility is designed to manufacture recombinant human insulin and insulin analogs to cater to the needs of people with diabetes in global markets.”

 

- Company Spokesperson

Video Credits: CNBC TV18

<< Back

 

 Download Company  Statement
 
 
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2016, Biocon. All Rights Reserved